CDKN2A mutations that prevent its binding to CDKs can lead to uncontrolled growth in various tumors, including NSCLC, PAAD, head and neck squamous cell carcinoma (HNSCC), and breast and ovarian cancers [147]. This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.